Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-09-14 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 5010M' on '14 September 2023'. This form is used to report changes in significant share ownership (crossing thresholds) by an individual or entity, which directly corresponds to the definition of a Major Shareholding Notification. The content details the resulting situation of voting rights and financial instruments held by JPMorgan Chase & Co. This fits the 'Major Shareholding Notification' category (MRQ) better than the general 'Regulatory Filings' (RNS), as MRQ is a specific type of regulatory disclosure concerning ownership thresholds.
2023-09-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange. The content is a 'TR-1: Standard form for notification of major holdings' detailing an 'acquisition or disposal of voting rights' by Barclays PLC, crossing a threshold. This type of mandatory disclosure regarding changes in significant share ownership directly corresponds to the Major Shareholding Notification category (MRQ). Although it is an RNS filing, the specific nature of the content (TR-1 major holding notification) makes MRQ the most precise classification over the general RNS fallback.
2023-09-13 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used in the context of a takeover bid (indicated by the reference to 'offeror/offeree' and 'Takeover Code') to disclose a person's interest or dealing in the securities of the target company (Dechra Pharmaceuticals plc). This type of disclosure, related to insider/significant shareholder activity during a takeover process, is best categorized under Director's Dealing (DIRS) or, more broadly, as a specific regulatory filing related to ownership changes. Since DIRS specifically covers director/executive trades, and this is a disclosure by a major shareholder (Millennium International Management LP) regarding a potential takeover, it falls under the scope of insider/significant ownership reporting. Given the options, 'Director's Dealing' (DIRS) is the closest fit for mandatory disclosure of security interests/dealings by insiders/major stakeholders, although it is specifically a Takeover Code disclosure. However, since it details dealings and positions of a significant holder during a potential M&A event, and there isn't a specific 'Takeover Disclosure' code, DIRS is the most appropriate category among the provided choices that covers personal security transactions/holdings disclosures. If the M&A context was the primary driver, TAR might be considered, but this form is about *dealing disclosure*, not the M&A announcement itself. Therefore, DIRS is selected as the best fit for a mandatory disclosure of security interests/dealings by a major party involved in a transaction.
2023-09-13 English
Form 8.3 - Dechra Pharmaceuticals PLC
Major Shareholding Notification Classification · 87% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code". This form is used to disclose interests and dealings in the securities of an offeror or offeree during a takeover situation. This specific disclosure relates to Dechra Pharmaceuticals PLC, which is subject to a takeover process. This type of filing, dealing disclosure by a major shareholder/stakeholder during a takeover, is not explicitly covered by the provided definitions (10-K, ER, IR, etc.). However, it is a mandatory regulatory disclosure related to insider/major shareholder activity during a corporate action (takeover). Among the options, "Director's Dealing (DIRS)" covers personal share transactions by executives, and while this is a major shareholder/fund manager, the context is highly specific to takeover rules. The closest fit among the provided codes that deals with insider/significant shareholder transactions is DIRS, although this form (Form 8.3) is distinct from standard insider dealing reports (like Form 3/4/5 in the US context). Given the options, and recognizing that this is a disclosure of dealings/positions by an interested party, DIRS is the most analogous category for insider/significant transaction reporting, even though the context is a takeover disclosure (TAR is for M&A activity announcement, not the dealing disclosure itself). Since it is a disclosure of dealings by a party involved in a potential transaction, and DIRS covers director dealings, I will classify it as DIRS as the best fit for reporting significant security transactions by an insider/major holder.
2023-09-13 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used in the context of a takeover bid (indicated by the reference to 'offeror/offeree' and the Takeover Code) to disclose a person's interest or dealing in the relevant securities. This type of disclosure, related to insider/significant shareholder activity during a takeover scenario, is best classified under Director's Dealing (DIRS) as it involves reporting personal share transactions/interests by a major holder, although it is specifically a Takeover Code disclosure. Given the options, DIRS covers insider/significant transaction reporting best, though it is not a standard Form 3/4/5. Since it deals with significant holdings and dealings related to a potential takeover, it falls under the scope of insider/director/major shareholder transaction reporting.
2023-09-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with 'RNS Number : 1533M' and contains the standard header/footer information associated with RNS (Regulatory News Service) announcements from the London Stock Exchange. The content details a 'TR-1: Standard form for notification of major holdings' by Barclays PLC regarding an acquisition/disposal of voting rights in Dechra Pharmaceuticals PLC, crossing a notification threshold. This type of filing, which reports changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although RNS is the distribution channel, the specific content dictates the MRQ classification over the general RNS fallback.
2023-09-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.